1. Home
  2. STVN vs RARE Comparison

STVN vs RARE Comparison

Compare STVN & RARE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • STVN
  • RARE
  • Stock Information
  • Founded
  • STVN 1949
  • RARE 2010
  • Country
  • STVN Italy
  • RARE United States
  • Employees
  • STVN N/A
  • RARE N/A
  • Industry
  • STVN Containers/Packaging
  • RARE Biotechnology: Pharmaceutical Preparations
  • Sector
  • STVN Consumer Discretionary
  • RARE Health Care
  • Exchange
  • STVN Nasdaq
  • RARE Nasdaq
  • Market Cap
  • STVN 6.3B
  • RARE 5.3B
  • IPO Year
  • STVN 2021
  • RARE 2014
  • Fundamental
  • Price
  • STVN $19.58
  • RARE $59.20
  • Analyst Decision
  • STVN Buy
  • RARE Strong Buy
  • Analyst Count
  • STVN 5
  • RARE 15
  • Target Price
  • STVN $30.60
  • RARE $87.47
  • AVG Volume (30 Days)
  • STVN 421.1K
  • RARE 644.1K
  • Earning Date
  • STVN 10-29-2024
  • RARE 10-31-2024
  • Dividend Yield
  • STVN 0.30%
  • RARE N/A
  • EPS Growth
  • STVN N/A
  • RARE N/A
  • EPS
  • STVN 0.49
  • RARE N/A
  • Revenue
  • STVN $1,165,359,477.00
  • RARE $481,303,000.00
  • Revenue This Year
  • STVN $2.82
  • RARE $26.02
  • Revenue Next Year
  • STVN $9.77
  • RARE $18.78
  • P/E Ratio
  • STVN $39.26
  • RARE N/A
  • Revenue Growth
  • STVN 5.53
  • RARE 19.47
  • 52 Week Low
  • STVN $16.56
  • RARE $31.52
  • 52 Week High
  • STVN $35.56
  • RARE $59.76
  • Technical
  • Relative Strength Index (RSI)
  • STVN 46.29
  • RARE 72.13
  • Support Level
  • STVN $19.26
  • RARE $54.94
  • Resistance Level
  • STVN $20.60
  • RARE $59.76
  • Average True Range (ATR)
  • STVN 1.22
  • RARE 1.60
  • MACD
  • STVN -0.14
  • RARE -0.13
  • Stochastic Oscillator
  • STVN 30.99
  • RARE 89.04

About STVN Stevanato Group S.p.A.

Stevanato Group SPA is a provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries. It delivers an integrated, end-to-end portfolio of products, processes, and services that address customer needs across the entire drug life cycle including development, clinical, and commercial stages. It has two segments; Biopharmaceutical and Diagnostic Solutions which generates key revenue, includes all the products, processes and services developed and provided for the containment and delivery of pharmaceutical and biotechnology drugs and reagents, as well as the production of diagnostic consumables. and its other segment is Engineering. Geographically, the company derives majority revenue from Europe, Middle East and Africa.

About RARE Ultragenyx Pharmaceutical Inc.

Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.

Share on Social Networks: